Hypothesis / aims of study: A novel intra-urethral catheter (IUC) has been developed that is self-retaining and employs a patient-controlled magnetic valve that allows the bladder to fill normally and to be emptied on demand, without external appliances. The sterile and disposable catheter can remain in the lower urinary tract for up to 30 days. It is inserted through the urethra and held in place in the bladder by a self-retaining Malecot. To void, the patient holds a small "actuator magnet" near the base of the penis, allowing urine flow (Figure 1 ). Withdrawing the actuator magnet allows the valve to close. Several of the design features of the IUC were demonstrated to be effective in an earlier study (1). This study evaluated the current improved version of the IUC in men with acute urinary retention.
SAFETY AND EFFICACY OF A PATIENT-CONTROLLED BLADDER MANAGEMENT SYSTEM FOR TREATING URINARY RETENTION IN MEN
Hypothesis / aims of study: A novel intra-urethral catheter (IUC) has been developed that is self-retaining and employs a patient-controlled magnetic valve that allows the bladder to fill normally and to be emptied on demand, without external appliances. The sterile and disposable catheter can remain in the lower urinary tract for up to 30 days. It is inserted through the urethra and held in place in the bladder by a self-retaining Malecot. To void, the patient holds a small "actuator magnet" near the base of the penis, allowing urine flow (Figure 1 ). Withdrawing the actuator magnet allows the valve to close. Several of the design features of the IUC were demonstrated to be effective in an earlier study (1) . This study evaluated the current improved version of the IUC in men with acute urinary retention.
Study design, materials, and methods: We enrolled18 men, at least 18 years old, who had acute urinary retention from nonneurogenic causes in a multicenter, prospective, non-randomized, open-label study. Men who required continuous bladder drainage or had a documented bladder capacity of less than 300 mL were excluded. Data were collected from patient diaries and from weekly follow-up visits during catheterization for up to 30 days. The primary endpoint was success in all of four conditions: proper placement of the catheter, uneventful removal, a post-void residual volume of 75 mL or less, and no adverse device-related events. Secondary outcome measures included Quality of Life assessment (2). The discrepancy between the number of valve actuations and closing is the result of missing data. Figure 1 . The Intra Urethral Catheter is held in place in the bladder by the malecot and a magnetic valve in the distal end blocks urinary flow until it is opened by the patient holding an actuator magnet near to the scrotum.
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